MEDP
Strong BuyPremium GrowerAI neutralMedpace Holdings, Inc. · Healthcare · United States · $17.2B
$604.25 +0.2% · close 7 Oct · scored 9 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
Read our full research report on MEDP (Jun 2026), freeDoes StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Medpace runs clinical trials for small and mid-sized biotech companies. It has industry-leading margins and returns on capital, and it has a long record of buying back its own shares. Second-quarter results showed strong revenue growth and record figures. Against that, insiders sold 0.87% of the shares over 90 days, a steady run of Form 4 filings, and the company's client base depends on biotech funding, which tends to tighten when rates stay high. The quality is real, but the timing is not compelling enough to call.
ABOUT MEDPACE HOLDINGS, INC.
Read
Medpace Holdings, Inc. is a global, full-service clinical contract research organization (CRO) providing clinical development services to biopharmaceutical and medical device companies. The company specializes in scientifically-driven clinical trials, particularly for small to mid-sized biopharma firms, offering a comprehensive and integrated approach. Its deep therapeutic expertise, operational efficiency, and focus on complex, high-quality trials provide a strong competitive moat within the specialized CRO market.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 1.5B | 1.9B | 2.1B | 2.5B | 20.1% | 2.8B | 2.9B | 3.0B | 9.5% |
| EPS | 5.06 | 7.57 | 9.20 | 13.06 | 15.64 | 32.6% | 17.02 | 18.12 | 19.77 | 12.4% |
| Shares | — | 31.1M | 30.8M | 30.6M | 28.4M | -8.8% | 27.9M | — | — | — |
| Debt | — | 188.9M | 142.1M | 126.2M | 113.6M | -15.6% | 144.1M | — | — | — |
| Equity | — | 386.4M | 559.0M | 825.5M | 459.1M | 5.9% | — | — | — | — |
| Op CF | — | 388.1M | 433.4M | 608.8M | 713.2M | 22.5% | 752.7M | — | — | — |
| Inv CF | — | -38.7M | -34.6M | -28.3M | -31.1M | — | — | — | — | — |
| Fin CF | — | -775.8M | -182.6M | -154.0M | -860.4M | — | — | — | — | — |
Swung more than 55% of stocks we rank over the past year (44% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MEDP are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MEDP | Medpace Holdings, Inc.(you) | $17.2B | 83 | Strong Buy |
| DGX | Quest Diagnostics Incorporated | $25.7B | 85 | Strong Buy |
| LH | Labcorp Holdings Inc. | $24.7B | 88 | Strong Buy |
| RVTY | Revvity, Inc. | $15.9B | 66 | Buy |
| ILMN | Illumina, Inc. | $38.6B | 77 | Buy |
| CRL | Charles River Laboratories International, Inc. | $13.4B | 65 | Buy |
| IQV | IQVIA Holdings Inc. | $44.1B | 79 | Buy |
| SHC | Sotera Health Company | $5.2B | 80 | Buy |
| A | Agilent Technologies, Inc. | $46.6B | 74 | Buy |
| VCYT | Veracyte, Inc. | $3.5B | 80 | Strong Buy |
Peer medians: ROE -31.5% · P/E 25.1x · Gross margin 63.3%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.